Latent transition analysis for longitudinal studies of post-acute infection syndromes
- Roy Gusinow
- Anna Górska
- Lorenzo Maria Canziani
- Iris Lopes-Rafegas
- Carolina Alvarez Garavito
- Adriana Tami
- Elisa Gentilotti
- Elisa Sicuri
- Cedric Laouenan
- Jade Ghosn
- Aline-Marie Florence
- Nadhem Lahfej
- Fulvia Mazzaferri
- Lidia Del Piccolo
- Maddalena Giannella
- Alice Toschi
- Michela Di Chiara
- Maria Giulia Caponcello
- Zaira R. Palacios-Baena
- Karin I. Wold
- Elisa Rossi
- Evelina Tacconelli
- Jan Hasenauer
- Elena Addis
- Maddalena Armellini
- Anna Maria Azzini
- Benedetta Barana
- Lucia Bonato
- Elena Carrara
- Alessandro Castelli
- Filippo Cioli Puviani
- Michela Conti
- Raffaella Cordioli
- Carmine Cutone
- Ruth Joanna Davis
- Pasquale De Nardo
- Miriam Emiliani
- Alessio Esposito
- Daniele Fasan
- Giada Fasani
- Giorgia Franchina
- Jacopo Garlasco
- Enrico Gibbin
- Salvatore Hermes Dall’O’
- Chiara Konishi De Toffoli
- Lorenza Lambertenghi
- Federico Lattanzi
- Andrea Leonardi
- Francesco Luca
- Gaia Maccarrone
2026-02-10
Post-Acute Infectious Syndromes (PAIS) refer to the symptoms persisting months after initial infection. Clinical research studies on this topic often collect rich, multi-modal datasets. Yet, the complexity of the datasets and the lack of a precise clinical case definition pose difficulties in creating comprehensive analyses. Here, we present a generalisable framework for analysing data from longitudinal studies of PAIS using Latent Transition Analysis (LTA). It enables the identification of disease phenotypes and the patient-level analysis of transitions between them, without relying on predefined clinical categorisations. Furthermore, we introduce a method for incorporating covariate information, which enables exploration of how patient characteristics influence disease trajectories. We apply this methodology to the ORCHESTRA dataset, composed of individuals affected by SARS-CoV-2 infection from multiple European centres, for investigation into Post-COVID-19 condition (PCC). 5094 patient assessments were collected at SARS-CoV-2 infection, and at 6, 12, 18, and 24 months of follow-up. Our model identifies distinct PCC phenotypes with patient trajectories impacted by age and sex. Our results highlight how LTA can enhance the interpretability of complex, time-resolved clinical data, support personalized patient monitoring and management, and accelerate therapeutic development for other PAISs, too.